Clinical Distribution Product

BuMA®

Biodegradable Polymer Drug-Eluting Coronary Stent engineered for controlled drug release and vascular healing.

For hospital and healthcare facility distribution only.

Product Overview

BuMA® is a biodegradable polymer sirolimus-eluting coronary stent built on a 316L stainless steel platform. The system is designed to deliver controlled drug release while maintaining mechanical stability during coronary intervention procedures. Its biodegradable polymer coating supports vascular healing following stent implantation.

Technical Specifications

Stent Platform316L Stainless Steel
PolymerPLGA Biodegradable Polymer
DrugSirolimus
Drug Elution Profile~100% Drug Release in 30 Days
Strut Thickness≈ 100 μm
Polymer Absorption2–3 Months
Available Diameters2.50 – 4.00 mm
Available Lengths10 – 35 mm

Product Platform Comparison

Both stent systems are engineered for coronary intervention, offering distinct technological approaches to drug elution and vascular healing strategy.

HT Supreme®
BuMA®
Polymer Type
Biodegradable Polymer
Biodegradable Polymer
Drug
Sirolimus
Sirolimus
Design Philosophy
Healing-Targeted Elution Strategy
Optimized Controlled Drug Release
Clinical Emphasis
Endothelial recovery support
Balanced healing & performance
Intended Use
Hospital & Interventional Use
Hospital & Interventional Use

Sirolimus Release Profile

BuMA® utilizes a biodegradable polymer coating designed to provide controlled sirolimus release, supporting vascular healing while reducing neointimal proliferation.

Relative Drug Concentration
Time (Days)

Controlled release kinetics under physiological conditions.

Clinical Evaluation

Clinical performance of BuMA® sirolimus-eluting stent has been evaluated under structured interventional cardiology protocols to assess safety and efficacy outcomes in coronary artery disease treatment.

Low
In-Stent Late Lumen Loss (LLL)
High
Procedural Success Rate
Favorable
Target Lesion Revascularization (TLR) Outcomes
Study Type Prospective Multicenter Evaluation
Indication De Novo Coronary Lesions
Primary Endpoint Angiographic & Clinical Safety Outcomes
Drug Sirolimus
Platform 316L Stainless Steel

Official Distribution

Distributed exclusively for hospital and interventional cardiology use.